Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Public Offering Announcement: Humacyte, Inc. has initiated an underwritten public offering of its common stock and plans to use the proceeds for commercialization of its product SYMVESS™, development of other candidates, and general corporate purposes.
Company Overview: Humacyte is a biotechnology company focused on creating bioengineered human tissues for medical applications, with products currently in late-stage clinical trials for various vascular conditions, including FDA-approved treatments for vascular trauma.
Trade with 70% Backtested Accuracy
Analyst Views on HUMA
About HUMA
About the author
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
